Compare PROF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | TLSI |
|---|---|---|
| Founded | N/A | 2010 |
| Country | Canada | United States |
| Employees | N/A | 110 |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.4M | 272.3M |
| IPO Year | 2017 | N/A |
| Metric | PROF | TLSI |
|---|---|---|
| Price | $7.05 | $5.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | $12.00 |
| AVG Volume (30 Days) | ★ 148.8K | 141.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $10,680,000.00 | N/A |
| Revenue This Year | $61.09 | $55.47 |
| Revenue Next Year | $120.94 | $40.05 |
| P/E Ratio | $6.18 | ★ N/A |
| Revenue Growth | ★ 48.35 | N/A |
| 52 Week Low | $3.90 | $3.42 |
| 52 Week High | $8.95 | $7.95 |
| Indicator | PROF | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 54.27 |
| Support Level | $7.00 | $4.90 |
| Resistance Level | $7.18 | $5.61 |
| Average True Range (ATR) | 0.42 | 0.32 |
| MACD | 0.07 | 0.11 |
| Stochastic Oscillator | 98.29 | 87.18 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.